SecBot SecBot
8-K ·Filed Nov 4, 2026

EWTX

Edgewise Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed12d 8h ago SEC0001104659-26-122654
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The reported EPS is dominated by a one-time gain and does not reflect operating performance. Focus on the upcoming Phase 3 initiation for EDG-7500 and Phase 2 data for EDG-15400 as the next catalysts. The $1.744 billion cash position provides ample runway for pipeline advancement.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

EWTX drug pipeline →

EDG-15400

● Neutral Named in this 8-K
Impact
Phase
Phase 1
Time to market
Unlikely before 2029-2030 at earliest — Phase 1 data pending, Phase 2 not yet initiated, and HFpEF Phase 3 trials typically take years
Next catalyst
None dated

What to watchEDG-15400 is too early-stage to drive meaningful share price moves in the near term. Watch for the Phase 2 HFpEF trial initiation (expected H2 2026) and eventual Phase 2 data (H1 2027). For EWTX, the more impactful near-term catalyst is the EDG-7500 Phase 3 trial initiation in HCM (Q4 2026). EDG-15400 is a pipeline extension story for now.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$38.87
T+0 close · Nov 4, 2026 · via day close
Latest settled
+17.88%
T+5 · $45.82 · next T+20 in 17d
Vs SPY
+14.59%
α at T+5
Latest observation
+12.29%
T+6 · FF3 residual α
  1. T+0 · Nov 5 $38.87entry
  2. T+1 · 11d ago +15.87%α +15.56% · $45.04
  3. T+5 · 5d ago +17.88%α +14.59% · $45.82
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Edgewise Therapeutics reported Q3 2026 net income of $1.166 billion ($9.65 diluted EPS), driven by a $1.348 billion gain on the sale of sevasemten to Servier, versus a net loss of $40.7 million a year ago. The company ended the quarter with $1.744 billion in cash and securities, initiated its Phase 2 EQUINOX-HFpEF trial for EDG-15400, and expects to start a Phase 3 trial for EDG-7500 in HCM by year-end 2026. The reported EPS of $9.65 far exceeded the consensus estimate of $2.51, but this reflects a one-time gain, not recurring operations.

Key Financial Metrics

EPS
$9.65
est $2.51 · +284.5%
Revenue
$0.00
est $0.00
Rating
beat

Key Facts

  • Net income of $1,166.2 million ($9.65 diluted EPS) vs net loss of $40.7 million ($0.39 loss per share) in Q3 2025
  • Gain on sevasemten sale of $1.348 billion recognized in Q3 2026
  • Cash, cash equivalents and marketable securities of $1,743.9 million as of September 30, 2026
  • Phase 3 trial for EDG-7500 in HCM on track to initiate by year-end 2026
  • First patient dosed in Phase 2 EQUINOX-HFpEF trial of EDG-15400
  • R&D expenses decreased to $31.6 million from $37.5 million year-over-year, reflecting lower sevasemten costs
  • G&A expenses increased to $14.6 million from $9.4 million year-over-year

Financial Impact

Net income of $1.166 billion vs consensus EPS estimate of $2.51, driven by a one-time $1.348 billion gain on asset sale

net incomeepscash position

Risk Factors

  • No revenue from product sales; company is pre-commercial
  • Substantial dependence on success of EDG-7500 and EDG-15400 clinical programs
  • Milestone payments from Servier transaction are contingent and not guaranteed
  • Operating expenses may increase as clinical programs advance

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-122654
Document: tm2628556d1_8k.htm0001104659-26-122654
Document: 0001104659-26-122654-index-headers.html0001104659-26-122654
Document: 0001104659-26-122654-index.html0001104659-26-122654
Document: 0001104659-26-122654.txt0001104659-26-122654
8-K Data (Synthetic)0001104659-26-122654

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026